We write to you in reference to recent media reports claiming that Remedium Lifecare Limited has received an order worth ?8,500 crore from Eli Lilly and Company. The reports further suggest that this order marks a significant milestone for our company and the Indian pharmaceutical sector.We would like to categorically state that these reports are entirely speculative and unfounded. Remedium Lifecare Limited has not entered into any such agreement or received any orders from Eli Lilly and Company, as mentioned in the media.As a responsible corporate entity, we remain committed to providing accurate and timely information to the exchange and our stakeholders in accordance with the applicable regulations. Should there be any material developments or agreements that require disclosure, we will notify the exchange in due course.We kindly request BSE to take note of this clarification and advise investors and stakeholders to refrain from relying on unverified media reports.
Rumour verification - Regulation 30(11)
Filed with BSE · · 1 page · English
Release
Earlier from Supha Pharmachem
- Supha Pharmachem Ltd Press Release Dec 24 2024
- Closure of Trading Window
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Supha Pharmachem Ltd Press Release Dec 23 2024
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Later from Supha Pharmachem
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Supha Pharmachem Ltd Press Release Jan 10 2025
- Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Supha Pharmachem Ltd Press Release Jan 17 2025
- Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, January 22, 2025.
Follow Supha Pharmachem into a list and get an email when it puts out news.
Follow Supha Pharmachem